{"name":"Senda Biosciences","slug":"senda","ticker":"Private","exchange":"Private","domain":"sendabio.com","description":"Senda Biosciences is a private biotechnology company focused on developing oral biologics for various therapeutic areas. The company is working on innovative drug delivery technologies to improve the efficacy and safety of biologic therapies. Senda Biosciences is positioned to address significant unmet needs in the pharmaceutical market.","hq":"Copenhagen, Denmark","founded":0,"employees":"","ceo":"Lars Hellmann","sector":"Drug Delivery / Oral Biologics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"SB-001 patent cliff ($0.00 at risk)","drug":"SB-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"deal","headline":"Senda Biosciences Raises $100M in Series C Funding","summary":"Senda Biosciences has secured $100 million in Series C funding to advance its oral biologics pipeline.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"trial","headline":"Senda Biosciences Announces Positive Phase 1 Results for SB-001","summary":"Senda Biosciences has reported positive Phase 1 results for its lead candidate, SB-001, demonstrating promising safety and efficacy profiles.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOaG5oYmUxOXdlRFRRQXMydEc0emVSWXhMUV9CSmJmMUdMUkVKSElaZjlOQmRVeXBOU1lia3huTl90d2wtS2lVSVpYb0Z2eWdoSG5Mb2hDbURrOUFiTFRjMmlvNnFaSGFRazZOekVvb1c0ck5sMnJLYWZ4dHhaMFVVYW9qWU5HTGNZU194S0wtaw?oc=5","date":"2024-05-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 of the best-funded private healthcare and biotech companies - drugdiscoverytrends.com","headline":"100 of the best-funded private healthcare and biotech companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQcHk4S1lUZWZkT3VFTzhDYy1mLXpNVzRRUlJueXMwYThDZlFfUjJhVVZhaWtTZWY5VTB3QUIxVk92ZjRlRTZ3akc1NzVQdW51NUdGNkxTX21XazcyaFhZalFsblV4TTdkOXZwTHpObmFvdC02b2NxSVhINVNKMFRuZ0ZRWDBGSHJWaXo3SzVPWFFlYVk?oc=5","date":"2023-10-19","type":"pipeline","source":"BioPharma Dive","summary":"Laronde, Senda Biosciences merge to create new Flagship company - BioPharma Dive","headline":"Laronde, Senda Biosciences merge to create new Flagship company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNaXM5SF9HWFEyUlk3bDIzUVZSazNRLVZBMTR2bkF6ZjVhMEV5dWVrVnlrTXMta2MyUlFvcWxoS1A2MDdNb200SGR6YklaV3dUYnU4WncySkFnenVHdjVNRUR0UXctTkplMktpdFFidlUyQWpLdnJjS0dxbjJ2VTBSY1FSYUNkVlRhQ2pwVDZDcXVQQQ?oc=5","date":"2022-08-16","type":"pipeline","source":"BioPharma Dive","summary":"Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise - BioPharma Dive","headline":"Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1SRW9keGhDTHNpVTVSeHlWV1FXdjdYUjFkN2xxU2tQRzR4ZDV6YTBHa0FJVWkzVWNhM2N2blJCN1hlWDYzTDJLeXY3UVFIczZva09aUFpndVdVOVVod25Vc1VDVWtaWks0ajZ3Mw?oc=5","date":"2020-07-16","type":"pipeline","source":"BioSpace","summary":"BioSpace Movers & Shakers, July 17 - BioSpace","headline":"BioSpace Movers & Shakers, July 17","sentiment":"neutral"}],"patents":[{"drugName":"SB-001","drugSlug":"sb-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Pfizer","Sanofi"],"therapeuticFocus":["Autoimmune Diseases","Cancer"],"financials":null,"yahoo":null}